Loading…
Aktis Oncology, Inc. is projected to rise to $30.40 by 2027, a +38% move from its current price of $22.07. AKTS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $21.28 | $22.07 | $22.89 | -0.01% |
| Aug 3 | $20.95 | $22.07 | $23.24 | -0.02% |
| Aug 4 | $20.71 | $22.06 | $23.51 | -0.03% |
| Aug 5 | $20.51 | $22.06 | $23.74 | -0.04% |
| Aug 6 | $20.33 | $22.06 | $23.94 | -0.04% |
| Aug 7 | $20.17 | $22.06 | $24.12 | -0.05% |
| Aug 8 | $20.02 | $22.06 | $24.30 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $20.02 | $22.06 | $24.30 | -0.06% |
| Week 2 | $19.22 | $22.04 | $25.27 | -0.12% |
| Week 3 | $18.63 | $22.03 | $26.05 | -0.19% |
| Week 4 | $18.14 | $22.02 | $26.71 | -0.25% |
| Week 5 | $17.72 | $22.00 | $27.31 | -0.31% |
| Week 6 | $17.35 | $21.99 | $27.87 | -0.37% |
| Week 7 | $17.01 | $21.97 | $28.38 | -0.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aktis Oncology, Inc. is a clinical-stage oncology company that engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
Its lead product candidates include [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform currently in Phase 1b trials for Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate and other solid tumors.
The company has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. It was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Aktis Oncology, Inc. (AKTS) is a healthcare company with a current price of $22.07 per share and a market capitalization of $1.22B.
The stock is ranked 2291.
Near-term price context shows a neutral technical stance. The RSI14 is 40 and the 50-day simple moving average (SMA50) sits at $23.89.
Forecasts imply a bullish longer-term trajectory, with 2026 averaging $22.07 (ROI 0%) and higher averages thereafter such as 2027 at $30.40, 2040 at $154.10, and 2050 at $261.78, with a 2050 max of $602.09.
A major floor 31.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 46.0% above — a clean break opens room to run.
A major ceiling 61.4% above — clearing it would confirm fresh momentum.
Key AKTS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AKTS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $22.93 | Sell | $22.86 | Sell |
| MA 10 | $23.59 | Sell | $23.59 | Sell |
| MA 20 | $25.09 | Sell | $24.44 | Sell |
| MA 50 | $23.89 | Sell | $23.89 | Sell |
| MA 100 | $21.29 | Buy | $22.62 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.30 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -132.41 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.53 | Sell |
| ROC (12) | -15.12 | Sell |
| Bollinger %B (20,2) | 0.10 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.07 | Sell |
| Awesome (5,34) | -2.97 | Sell |
| Ultimate (7,14,28) | 26.63 | Buy |
| Momentum (10) | -2.82 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 22.17 | Sell |
| ADX (14) | 15.99 | Neutral |
| ATR (14) | 0.88 | Info |
The 30-day technical picture is NEUTRAL.
RSI 14 is 40, indicating neither overbought nor oversold conditions. The SMA50 is $23.89, placing the near-term price slightly above the short-term trend line.
A near-term support level is at $22.07 and the resistance is at $32.23. The 30-day trading range runs from $17.34 to $28.08, reflecting a relatively wide swing within the month. The stock’s annualized volatility is 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.19 | $22.07 | $30.25 | 0% | Neutral | |
| $22.02 | $30.40 | $45.37 | +38% | Bullish | |
| $29.33 | $43.15 | $68.81 | +96% | Bullish | |
| $28.22 | $43.83 | $73.49 | +99% | Bullish | |
| $29.56 | $48.23 | $84.28 | +119% | Bullish | |
| $32.46 | $55.44 | $100.38 | +151% | Bullish | |
| $30.66 | $54.73 | $102.25 | +148% | Bullish | |
| $37.11 | $69.12 | $132.80 | +213% | Bullish | |
| $45.10 | $87.53 | $172.51 | +297% | Bullish | |
| $46.93 | $94.85 | $191.39 | +330% | Bullish | |
| $69.35 | $154.10 | $342.32 | +598% | Bullish | |
| $117.80 | $261.78 | $602.09 | +10.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $15.19 | $22.07 | $26.90 | +0.00% |
| September 2026 | $17.24 | $21.02 | $26.78 | -4.76% |
| October 2026 | $17.71 | $21.89 | $28.46 | +4.15% |
| November 2026 | $18.19 | $22.75 | $30.06 | +3.92% |
| December 2026 | $17.85 | $22.56 | $30.25 | -0.82% |
Click any year to see its month-by-month AKTS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AKTS could reach as high as $30.25, with a base case around $22.07 and support toward $15.19 — roughly 0% from $22.07. Price action looks broadly range-bound.
Expect AKTS to range from $22.02 to $45.37 through 2027. The $30.40 average target implies a +38% move from current prices. That is up +38% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The AKTS price prediction for 2028 points to an average of $43.15 (low $29.33, high $68.81) — a potential gain of +96% on today's $22.07. Momentum favours further upside here.
In 2029, AKTS is projected to trade between $28.22 and $73.49, averaging $43.83 — a potential gain of +99% from today's $22.07. That is up +2% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Aktis Oncology, Inc.'s 2030 outlook centres on $48.23, within a $29.56 to $84.28 range. That is up +10% on the projected 2029 average. That marks a +119% change versus current levels. Momentum favours further upside here.
By 2031, AKTS could reach as high as $100.38, with a base case around $55.44 and support toward $32.46 — roughly +151% from $22.07. Buyers look set to stay in control over this stretch.
Expect AKTS to range from $30.66 to $102.25 through 2032. The $54.73 average target implies a +148% move from current prices. That is -1% versus the projected 2031 average. Momentum favours further upside here.
The AKTS price prediction for 2033 points to an average of $69.12 (low $37.11, high $132.80) — a potential gain of +213% on today's $22.07. Buyers look set to stay in control over this stretch.
In 2034, AKTS is projected to trade between $45.10 and $172.51, averaging $87.53 — a potential gain of +297% from today's $22.07. That is up +27% on the projected 2033 average. Momentum favours further upside here.
Aktis Oncology, Inc.'s 2035 outlook centres on $94.85, within a $46.93 to $191.39 range. That is up +8% on the projected 2034 average. That marks a +330% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, AKTS could reach as high as $342.32, with a base case around $154.10 and support toward $69.35 — roughly +598% from $22.07. Momentum favours further upside here.
Expect AKTS to range from $117.80 to $602.09 through 2050. The $261.78 average target implies a +10.9x move from current prices. That is up +70% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AKTS today (≈ 45.310376 AKTS) could be worth
$11,861.28
+$10,861.28 (+1086%) by 2050 · US Dollar
Based on the average projected AKTS price of $261.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AKTSwould be worth at today's price.
$1,000 invested in AKTS on Jan 9, 2026 (≈ 44.642858 AKTS) would be worth
$985.27
-$14.73 (-1.5%) today · 0.99× · US Dollar
Based on a AKTS entry price of $22.4 vs. today's $22.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.89 | $923.82 | -7.6% |
| 1 month ago | $30.89 | $714.47 | -28.6% |
| 3 months ago | $19.42 | $1,136.46 | +13.6% |
| 6 months ago | $21.98 | $1,004.09 | +0.4% |
| All time ago | $22.4 | $985.27 | -1.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AKTS forecast.
Our base-case forecast reaches $44.00 around 2030.
Implied market cap at $44.00: $2.35B
The multi-year forecast depicts a bullish path with steadily higher average prices and strong long-run ROIs. In 2027 the average price is projected at $30.40 with a 37.7% ROI, followed by 2028 at $43.15 (95.5%), 2029 at $43.83 (98.6%), and 2030 at $48.23 (118.5%). By 2035 the average price is forecast at $94.85 and the trajectory continues higher with 2040 averaging $154.10 (598.3%) and 2050 averaging $261.78 (1086.1%), with the 2050 peak reaching $602.09.
The forecast for 2030 shows a bullish sentiment, as do later years, reflecting a sustained bullish outlook through 2050.
These are estimates, not guarantees, and actual results may vary.
Tap a question to reveal the answer.
2029 min $28.22, avg $43.83, max $73.49; 2030 min $29.56, avg $48.23, max $84.28; ROI 118.5%; Sentiment BULLISH.
The forecast shows bullish sentiment starting in 2027 and rising averages through 2050, with 2027 avg $30.40, 2040 avg $154.10, and 2050 avg $261.78; ROI peaks at 1086.1% in 2050, indicating a strong long-run upside in the provided scenario.
Yes. The forecast includes a 2030 max of $84.28 and a 2029 max of $73.49, indicating the possibility of prices exceeding $60 in coming years.
2050 min $117.80, avg $261.78, max $602.09; ROI 1086.1%; Sentiment BULLISH.
Annualized volatility is 70%.
Aktis Oncology, Inc. Community Discussion
0Share your Aktis Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.